What are the most common side effects of Polivy?
Polivy (polatuzumab vedotin-piiq), used with bendamustine and rituximab for relapsed or refractory diffuse large B-cell lymphoma, has these frequent adverse reactions (occurring in ≥20% of patients in clinical trials): neutropenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, pyrexia, reduced appetite, and pneumonia.[1]
How severe are these reactions and what causes them?
Most reactions are linked to Polivy's antibody-drug conjugate mechanism, where the drug monomethyl auristatin E disrupts microtubules in cancer cells but also affects healthy ones. Neutropenia (49%), thrombocytopenia (43%), and anemia (41%) dominate due to bone marrow suppression; peripheral neuropathy (40%) stems from nerve damage and may worsen with cumulative doses.[1] Severe (Grade 3-4) cases hit 46% for neutropenia and 30% for thrombocytopenia.
What monitoring or management do doctors recommend?
Guidelines call for frequent blood counts, neuropathy assessments before each cycle, and dose delays or reductions for Grade 2+ neuropathy or hematologic toxicity. Prophylactic G-CSF reduces neutropenia risk; discontinue for Grade 2 neuropathy not improving or any Grade 3-4.[1]
How does Polivy compare to other lymphoma treatments?
In the GO29365 trial, Polivy combo showed higher rates of peripheral neuropathy (40% vs 2% with BR alone) and fatigue (31% vs 26%), but improved survival. Compared to CAR-T therapies like axicabtagene ciloleucel, Polivy has fewer cytokine release syndrome cases but more cytopenias.[1][2]
Are there long-term risks patients worry about?
Peripheral neuropathy persists post-treatment in 30-40% of cases, sometimes irreversible. Infections from neutropenia affect 26%; secondary malignancies occurred in 1.5%.[1] Patients often search for neuropathy relief strategies like gabapentin or physical therapy.
[1]: Polivy Prescribing Information (Genentech, 2023)
[2]: GO29365 Trial Data (NEJM, 2019)